Adults over the age of 65 constitute 13% of the global population and are the fastest growing demographic subgroup; this group is expected to reach 2.1 billion people in 2050 (ref.
and mortality, and highlight evidence-based and novel therapies targeting this high-risk population.
Biological pathways to sarcopenic obesity Age-related changes in body composition. Multiple factors are responsible for changes to body composition with ageing. Body fat increases until the seventh decade of life and thereafter decreases 13, 14 . Vertebral compression results in a reduction in height 15 , which affects anthropometric measures such as BMI. Muscle mass declines after peaking in the fourth decade 16 , such that weight is mostly gained as fat rather than lean mass. This age-related reduction in lean mass 17, 18 accounts, in part, for reduced resting metabolic rates 19 . Other aetiological factors that cause a decline in resting metabolic rates include reduced physical activity 20 , reduced mitochondrial volume and reduced oxidative capacity 21, 22 . Age-related decreases in the components of total energy expenditure (such as, resting metabolic rates, thermic effect of food and physical activity) contribute largely to the gradual increase in body fat.
The age-related decline in resting metabolic rates can also result from factors independent of changes to body composition, such as adaptive thermogenesis 23, 24 , Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies John A. Batsis 1, 2 * and Dennis T. Villareal 3, 4 Abstract | The prevalence of obesity in combination with sarcopenia (the age-related loss of muscle mass and strength or physical function) is increasing in adults aged 65 years and older. A major subset of adults over the age of 65 is now classified as having sarcopenic obesity , a high-risk geriatric syndrome predominantly observed in an ageing population that is at risk of synergistic complications from both sarcopenia and obesity. This Review discusses pathways and mechanisms leading to muscle impairment in older adults with obesity. We explore sex-specific hormonal changes, inflammatory pathways and myocellular mechanisms leading to the development of sarcopenic obesity. We discuss the evolution, controversies and challenges in defining sarcopenic obesity and present current body composition modalities used to assess this condition. Epidemiological surveys form the basis of defining its prevalence and consequences beyond comorbidity and mortality. Current treatment strategies, and the evidence supporting them, are outlined, with a focus on calorie restriction, protein supplementation and aerobic and resistance exercises. We also describe weight loss-induced complications in patients with sarcopenic obesity that are relevant to clinical management. Finally , we review novel and potential future therapies including testosterone, selective androgen receptor modulators, myostatin inhibitors, ghrelin analogues, vitamin K and mesenchymal stem cell therapy.
which is considered a defence mechanism against weight loss 25 . The reduction in energy expenditure as we age is not proportionally associated with a reduced drive to eat, which furthers fat build-up and leads to small yearly positive changes in energy balance that might lead to weight gain [25] [26] [27] . Considerable inter-individual variability to weight loss suggests that adaptive thermogenesis plays a part in energy balance 28 in sarcopenic obesity. Muscle mass loss with ageing 29 correlates with decreased resting metabolic rates and metabolic adaptation, which perpetuates the development of obesity [30] [31] [32] . As most individuals with sarcopenic obesity are sedentary, small changes in their muscle mass can markedly alter daily energy expenditure, which in turn affects adaptive thermogenesis and exacerbates a vicious cycle in their metabolic development [33] [34] [35] [36] . Sex-specific hormonal changes: oestrogen and testosterone. Sex-specific changes in muscle and fat composition are partly due to age-related changes in oestrogen and testosterone. In women, menopause increases body weight and fat mass, specifically in visceral areas 37 , but decreases fat-free mass 38 . This shift in fat deposition to the centre of the body (which accounts for 15-20% of total fat stores) expands waist circumference and reduces muscle mass [38] [39] [40] . Oestrogen can attenuate these changes 41 by modulating inflammation in skeletal muscle through satellite cell activation 42, 43 . In males, testosterone promotes muscle regeneration through satellite cell activation 44, 45 . Testosterone levels decline by approximately 1% per year, which can negatively affect muscle mass and fat distribution in ageing 46 . Testosterone levels in the highest quartile (496-1,340 nmol/l) are associated with reduced lean muscle loss 47 and reduced visceral fat redistribution 48 in older men aged ≥65 years and in individuals with obesity 49 . Testosterone increases muscle protein synthesis by increasing amino acids utilization in skeletal muscle and increases androgen receptor expression 44, 45, 50 . Current data on supplementation for muscle strengthening are conflicting 51, 52 . A 2016 study reported that treatment with testosterone for 1 year did not improve physical function in men >65 years of age with agereduced levels of testosterone (serum testosterone concentration <275 ng/dl) 53 . Levels of dehydroepiandrosterone sulfate, the biological precursor of testosterone, also decrease with age in both men and women 54, 55 (for a comprehensive review on the effects of testosterone on body composition see ref.
).
Inflammatory pathways. A number of inflammatory pathways are common to muscle and visceral fat. Obesity activates macrophages, mast cells and T lymphocytes, promoting a low-level inflammation that results in the secretion of tumour necrosis factor (TNF), leptin and growth hormone (GH) [57] [58] [59] . All such secretory changes lead to insulin resistance, which is increased by muscle catabolism 60 , promoting gain in fat mass and a loss of muscle mass 57 . Leptin upregulates the pro-inflammatory cytokines IL-6 and TNF, which results in a reduction in the anabolic actions of insulinlike growth factor 1 (IGF1) 61 . This reduction in IGF1, along with the age-related reductions in testosterone, increases the likelihood of incident frailty 62 . Elevated cytokine levels observed in hypogonadal states are associated with truncal obesity, which exacerbates the development of sarcopenia 44, 45 . Adiponectin is negatively correlated with age and obesity and counters the effects of leptin. Elevated TNF directly inhibits adiponectin 63 , arresting muscle protein synthesis and mitochondrial processes 64 . Obesity also induces leptin resistance, promoting reduced muscle fatty oxidation and ectopic fat deposition 65, 66 .
Myocellular mechanisms.
A number of mechanisms might explain the reduction of muscle mass and strength in sarcopenic obesity, including type II muscle fibre atrophy, reduction in motor neurons, collagen deposition and fibre necrosis [67] [68] [69] [70] . Older adults (those ≥65 years) are at risk of developing anabolic resistance owing to reduced post-prandial amino acid availability, reduced muscle perfusion and a reduced digestive capacity resulting from splanchnic sequestration of amino acids 71 . Ageing stimulates the infiltration of fat into muscle 72, 73 , which might negatively affect sarcopenia 74 , as described below, and obesity promotes the deposition of fat in the liver, heart, pancreas and skeletal muscle ( fig. 1 ). The deposition of intramyocellular lipids promotes lipotoxicity and inflammation and induces dedifferentiation of mesenchymal adipocyte-like progenitor cells that express fatty tissue genes 75 . The regeneration potential of muscle is impaired, which might promote fibrosis, thereby promoting insulin resistance [76] [77] [78] [79] , partially owing to impaired mitochondrial fatty acid oxidation and increased lipolysis 76, 80 . A reduction in the number of mitochondria and elevated production of reactive oxygen species occur in muscle following the deposition of intramyocellular lipids. This process can impair muscle function and might reduce the oxidative capacity of muscle 81 . Potential mechanisms explaining these changes include age-related reductions in proteasome activity, deficiencies in ubiquitylation and autophagy and impairments in removing degraded proteins and end products [82] [83] [84] .
Key points
• Body composition changes that occur with the ageing process can lead to sarcopenic obesity, an increasingly prevalent disorder owing to the increased prevalence of obesity in an ageing population.
• Hormonal, inflammatory and myocellular mechanisms impact underlying biological processes that promote fat deposition and loss of lean mass and strength.
• Definitions of sarcopenia and obesity can vary considerably, prompting difficulties in the diagnosis and epidemiological understanding of sarcopenic obesity as well as the development of treatment strategies for this disease.
• lifestyle interventions including calorie restriction and physical activity consisting of aerobic and resistance exercises are the cornerstones of therapy.
• Clinicians and researchers need to be aware of weight loss-induced sarcopenia and osteopenia.
• Novel, promising therapies, including weight loss medications, bariatric surgery, whole-body vibration therapy, periodization (a systematic variation in physical training specificity, intensity and volume within periods), testosterone, selective androgen receptor modulators, anamorelin, myostatin inhibitors, vitamin K and mesenchymal stem cells, require further investigation.
Sarcopenia
The loss of muscle mass, strength or physical function with age.
Oxidative capacity
The maximal ability of muscle to utilize oxygen per g of muscle per hour.
Thermic effect of food
The amount of energy expended owing to the body's processing and storage of food.
Fat-free mass
A term interchangeably used with muscle mass and lean mass; it refers to the mass of all visceral organs, muscles (smooth and skeletal), bones, ligaments and tendons but does not include fat that is present in the marrow of bones or internal organs.
Pro-inflammatory lipids also secrete paracrine hormones and cytokines that promote a feedforward cycle by producing intramyocellular lipids. This lipotoxicity impairs muscle fibre contractility and interferes with muscle protein synthesis, exacerbating sarcopenia [82] [83] [84] . Lipid deposition can also occur in spaces previously occupied by muscle, impairing new muscle tissue growth. One study reported an increase in intramyocellular lipid deposition after young, healthy men and women aged 19-28 years were exposed to 30 days of leg disuse, which resulted in lower extremity muscle mass loss 85 . This finding could be due to skeletal muscle preferentially depositing fat for a source of energy as opposed to glucose 86, 87 . While muscle cells can regenerate through satellite mesenchymal progenitor cells, their numbers decline with age, which contributes to reduced muscle function 88, 89 . Myostatin can be upregulated in skeletal muscle, inhibiting muscle genesis 90 . In sum, individuals with obesity are at risk of inflammation, which can lead to the preferential mobilization of muscle instead of fat 91 .
The role of exercise. Exercise can affect hormonal balance, reduce oxidative stress, induce mitochondrial synthesis, alter immunological and motor function and improve muscle oxidative capacity [92] [93] [94] [95] . Increased muscle protein synthesis with exercise sensitizes muscle insulin action and promotes anabolism [96] [97] [98] [99] [100] . Sarcopenia is associated with reduced muscle protein synthesis, partly owing to decreased anabolic stimulation (which can result from a lack of regular exercise). Aerobic exercise 101 , resistance training [102] [103] [104] and their combination 105 increase muscle protein synthesis in older adults despite age-related decreases in anabolic signalling [106] [107] [108] [109] . Muscle satellite cells located between myofibres and their surrounding basal lamina are recruited into existing muscle fibres by physical activity 110, 111 . Muscle injury activates satellite cells to regenerate muscle by releasing IGF1, fibroblast growth factor and mechano growth factor, all of which stimulate the differentiation and proliferation of muscle satellite cells 112, 113 . Circulating inflammatory biomarkers, including IL-6, C-reactive protein and TNF, are downregulated by aerobic exercise and strength training, although the relationship is less clear with combined aerobic and resistance activities [114] [115] [116] [117] [118] . Elevated levels of IL-6 and TNF and low levels of IGF1 are associated with reduced muscle mass, reduced muscle strength, reduced muscle mobility and reduced muscle function, suggesting a marked role of exercise in attenuating these muscular changes with ageing 117, 119, 120 . Aerobic activity can improve the oxidative capacity of muscle by counteracting the negative effect of intramyocellular lipids and accelerating lipolysis, which results in an increase in capillary density 121 . The synthesis of mitochondria in myocytes is upregulated to meet the demands associated with an increase in capillary density, which in turn leads to increased oxygen extraction and metabolism 122 through the induction of calcium and metabolic signalling pathways such as those involving 5′-AMP-activated serine/threonine-protein kinase (AMPK) and sirtuins 123 . These mediators stimulate mitochondrial production, which promotes improved fatty acid metabolism 124 . Myocyte apoptosis can be abrogated by physical activity 125, 126 , while mechanisms of cellular quality control, including autophagy, mitophagy and mitochondriogenesis 127 , contribute to the development of sarcopenic obesity and could be potential targets for therapy. Reduced cytokine production can lead to improved glucose metabolism, insulin sensitivity and muscle protein synthesis, which might dampen the progression of sarcopenic obesity.
Ageing leads to reduced cardiopulmonary status owing to inefficient oxygen extraction and a concomitant reduction in metabolically active muscle mass 128 . Peak oxygen consumption is potentially inversely related to frailty 129, 130 , suggesting that improvements in VO2 max following aerobic training counteract frailty 131, 132 . Following a 12-week diet-exercise intervention in male and female frail adults with obesity aged 69 ± 1 years, investigators reported reduced skeletal muscle levels of mRNA for TLR4, IL6 and TNF, increased mechano growth factor mRNA and increased fat-free mass in the exercise group, and these results were independent of weight loss 133 . Separately, resistance exercises resulted in increased TNF mRNA and protein from skeletal muscle biopsy samples in frail adults 134 . Expression of skeletal muscle TNF, IL-1β and nitric oxide synthase, inducible in patients with heart failure was reduced following aerobic training, suggesting that aerobic exercise has anti-inflammatory effects 135 . Furthermore, a 12-week aerobic and resistance programme increased serum levels of ghrelin and adiponectin by 47% and 55%, respectively, and reduced circulating levels of CD14 + and CD16 + inflammatory monocytes, adding additional evidence to the anti-inflammatory effects of exercise 136 . Resistance exercise increases the number and size of fast twitching muscle fibres (IIA and IIX), which improve glucose metabolism in muscle and muscle protein synthesis 102, 103, [137] [138] [139] . Muscle protein synthesis is also improved by nutrient-stimulated vasodilation and nutrient transport to local muscle myofibrils 112, 124 . Muscle fascicle length and muscle tendon stiffness reportedly increased after strength training (leg press and extension) over 14 weeks in a cohort of men and women aged over 65 years 140 . In a study of eight young adults (aged 18-29 years) and seven older adults (aged 67-81 years), isometric knee extension at varying degrees of maximal voluntary contraction followed by a 6-week resistance programme demonstrated early increases of isometric knee extensor maximal force (which is a marker of voluntary muscle contraction) and increases in motor unit discharge rates (which is a magnitude of the speed of neural activation) 141 . Resistance training has also been shown to reduce levels of cytokines, such as resistin, leptin and IL-6 (ref.
142
).
Leptin and adiponectin stimulate and inhibit, respectively, the deposition of intramuscular lipids (fig. 1) ; however, defining their precise roles in physical activity continues to be challenging. For instance, the concentration of leptin in the systemic circulation is suppressed following resistance exercise 143 but also in individuals with overweight or obesity following a physical training intervention [143] [144] [145] . Resistance training seems to be more efficient in reducing leptin levels than aerobic training alone 146 , though conflicting evidence exists 147 . A study into the effects of aerobic activity in patients who had recovered from breast cancer reported that individuals who were randomized to the aerobic exercise group demonstrated reductions in insulin and leptin and increases in the adiponectin:leptin ratio but no significant changes in adiponectin compared with participants in the usual activity group 148 . These results parallel those from studies in inactive men aged 65-82 years who were overweight. Investigators assigned participants to partake in varying intensities of resistance exercises. The investigators reported no alterations in concentrations of leptin, but participants had intensity-dependent changes in adiponectin 139, 145 -high-intensity resistance training led to an increase in the concentrations of adiponectin for 24 hours after exercise in inactive adults who were overweight 139 .
Summary of mechanisms.
The core biological factors that underlie sarcopenic obesity are age-related changes in metabolism and body composition and the presence of concurrent environmental obesogenic factors and physical illnesses that develop with the ageing process. Incremental metabolic changes over time promote fat deposition with a pro-inflammatory cascade of events. In tandem, crosstalk with biologically active muscle tissue leads to a negative feedback cycle that promotes progressive gain in fat mass and loss of lean mass and muscle strength. In a pre-frail and frail population, a strategy combining physical training and nutritional intervention was more likely to result in stable or reduced IL-6 levels in individuals who demonstrated improved physical performance than in those with lower physical performance 149 . Calorie restriction and physical activity might impede and halt these processes. While we have a better understanding of the role of physical activity in reversing sarcopenic obesity, the effect of a lifetime of inactivity on the development of sarcopenic obesity is still unclear.
Assessing body composition
Gold standard methods to assess body composition, including CT and MRI, allow clinicians to accurately analyse adipose tissue and muscle mass 150 ( fig. 2 ). Steven Heymsfield and colleagues have argued the importance of using measures beyond muscle mass when diagnosing sarcopenic obesity 151 . The strengths and limitations of each method to assess body composition to diagnose sarcopenia and sarcopenic obesity have been reviewed elsewhere [152] [153] [154] [155] . Dual-energy X-ray absorptiometry (DXA) is recommended for the assessment of appendicular lean mass in the diagnosis of sarcopenia 156 owing to its affordability, availability and diagnostic accuracy 157 . DXA correlates well with gold standard measures of body composition, such as MRI, and with bioelectrical impedance, which can also measure fat and segmental muscle mass [158] [159] [160] . Assessments of lean mass are highly reproducible and can be used for clinical monitoring, while a detailed assessment of visceral fat is not as accurate 150, [161] [162] [163] . In a 2013 report by the International Society for Clinical Densitometry, the recommendation to perform DXA for assessing total body composition and for a regional analysis of fat and muscle in patients with muscle weakness or poor physical function was categorized as fair 157 .
VO2 max
The maximal amount of oxygen used per kg of body weight during maximal exercise.
Lean mass
A term that refers to the mass of all visceral organs, muscles (smooth and skeletal), bones, ligaments and tendons but excludes fat from bone.
Appendicular lean mass
Muscle mass consisting of the sum of the upper and lower limbs.
Bioelectrical impedance is a simple, non-invasive, inexpensive, rapid and portable diagnostic tool. Reductions in muscle mass result in an increase in connective tissue [164] [165] [166] that can interfere with the assessment of muscle mass. Variable hydration status also impacts its accuracy 167 . To use bioelectrical impedance, tissue hydration must be constant and the body must be cylindrical 168, 169 ; both assumptions are challenged in sarcopenia and obesity. Thus, an overestimation of the total volume of water and extracellular fluid in the body leads to aberrant values. Further, whether the bioelectrical impedance prediction equations are valid when applied to different ethnic groups is unclear 170 , despite specific adaptations and adjustments [171] [172] [173] . Biological differences between different ethnic populations might influence the relationship between skeletal mass and resistance 174 . Other notable limitations include large standard errors and population specificity 175 . Cut-off points might not capture such determinants, particularly when levels of fat mass are high, which questions the utility of bioelectrical impedance for the assessment of body composition by professional societies 169 who recommend adjustment to population-specific, age-appropriate equations 169, 176 . Further validation of bioelectrical impedance results is needed in individuals aged ≥80 years, as they are at increased risk of sarcopenic obesity 177, 178 . Of note, current bioelectrical impedance systems permit an improved protocol that involves segmental analyses in clinical settings, as reviewed elsewhere 179 .
An evolving definition
The current definitions of sarcopenic obesity are based on the individual definitions of sarcopenia and obesity (TAble 1) , but presently there is no consensus that defines the cut-off points for either of these diseases, which makes arriving at an accurate diagnosis of sarcopenic obesity challenging. The term sarcopenia is defined differently throughout the literature ( 156 identified sarcopenia cut-off points and tools for its measurement. They recognized the lack of diagnostic criteria for sarcopenia but integrated low muscle mass and function (strength or performance) in their terminology, believing that the relationship between these two measures is not linear nor bidirectional 73, 156, 181 . This algorithm was meant for clinical application using gait speed (<0.8 m/s) before muscle mass or strength measurement. EWGSOP recommended that muscle mass is assessed by DXA or bioelectrical impedance, using mathematical thresholds and formulas presented in their consensus document. Hand grip strength cut-off points are dependent on an individual's BMI.
The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project 182 suggested a causal, indirect relationship between muscle mass and function in their definition of sarcopenia. The FNIH suggested testing for low lean mass using DXA (defined using appendicular lean mass) and reduced muscle function using handgrip strength. FNIH stated that sex-specific cut-off points could be adjusted for BMI. The separate criteria for muscle mass and strength implied the need to target interventions for individuals with low mass or low strength. FNIH deliberately avoided the term sarcopenia to differentiate between qualitative (strength) and quantitative (mass) components.
These definitions provide excellent negative percent agreements on the absence of sarcopenia; however, there is poor overlap in identifying individuals with sarcopenia 183 . Ethnic-specific differences result in inaccurate prevalence estimates 184 . The Asian Working Group for Sarcopenia 185 provided guidance for individuals of Asian descent. They suggested using handgrip strength and gait speed for initial testing and/or screening followed by the EWGSOP approach for muscle mass measurement, strength and physical performance, with different, lower, cut-off points (TAble 1) .
Obesity is defined as an unhealthy excess body fat that increases the risk of medical illness and mortality 186 . As with sarcopenia, no consensus defines obesity cutoff points. Instead, cut-off points are premised on sexspecific, whole-body DXA. The American Association of Clinical Endocrinology 187 recommends the use of the WHO body fat thresholds for the diagnosis of obesity -(men >25% body fat and women >35% body fat). The WHO thresholds also used BMI for obesity (≥30 kg/m 2 ) or waist circumference (men ≥102 cm and women ≥88 cm) as a visceral fat surrogate. The International Society of Clinical Densitometry, the American Heart Association and The Obesity Society all recognize the lack of specific thresholds, while the American College of Sports Medicine suggests cut-off points of 28% and 35% for men and women, respectively 188, 189 . Others applied mathematical body fat thresholds of reference populations to provide sufficient power that might not be based on distal outcomes 190, 191 . Body fat has better predictive validity on the development of the metabolic syndrome 192 and cardiovascular disease risk 193 than BMI. 
Grip strength
A measurement used in the ascertainment of upper extremity strength; it is assessed using the dominant hand with a hand-held dynamometer. Body composition modalities have advantages and disadvantages in assessing changes in fat or muscle distribution. We suggest DXA for research purposes, as it is more readily available to provide the necessary information. If DXA is unavailable, a stand-alone or portable bioelectrical impedance system can be used. We advocate caution when using bioelectrical impedance equations; they must account for age, sex, levels of physical activity, body fat and ethnicity. Feasible anthropometric indices as surrogates for adiposity, including BMI and waist circumference, have poor sensitivity. In one study, BMI correctly classified 41.0% of men and 45.1% of women as being obese and waist circumference correctly classified 64.2% of men and 81.0% of women as being obese 194 . We believe that anthropometric measures should be used with great caution when assessing body composition and only if other imaging is unavailable.
With ageing, fat preferentially accumulates both viscerally and ectopically rather than as abdominal subcutaneous fat. Rapid accumulation of intra-abdominal fat is exacerbated by physical inactivity, hormonal changes, reduced responsiveness to thyroid hormone and leptin resistance 186 . As central fat accumulation predominates, and loss of muscle occurs peripherally, the prototype of sarcopenic obesity is easily recognized ('fat frail'). This prototype is not inconsistent with intramuscular fat accumulation, which contributes to inflammation, mitochondrial dysfunction and insulin resistance within muscle and reduces muscle protein synthesis 74, 195 .
Prevalence of sarcopenic obesity A shortcoming in ascertaining accurate prevalence rates for sarcopenic obesity is the lack of a consistent definition for either sarcopenia or obesity. A review of eight definitions for sarcopenic obesity noted a 19-fold to 26-fold variation in sex-specific rates 178 . The analysis showed that definitions for sarcopenia were highly dependent on mathematical thresholds, reference populations and muscle mass definitions. A comparison of the rates of sarcopenic obesity using bioelectrical impedance to define sarcopenia and percentage of body fat to define obesity showed increasing rates with age 196 . In another study, the authors identified individuals with a BMI ≥35 kg/m 2 and evaluated the prevalence of sarcopenic obesity using DXA-defined body fat in 120 predominantly female adults (46.9 ± 11.0 years). The investigators reported rates that ranged from 0-84.5% in women to 0-100% in males depending upon the definition applied 197 . In a population-based cohort using National Health and Nutrition Examination Survey (NHANES) data that applied the aforementioned FNIH criteria for appendicular lean mass, rates of sarcopenic obesity were 12.6% in men and 33.5% in women. The rates of sarcopenic obesity increased with age, reaching 48.0% and 27.5% in females and males, respectively, in those aged over 80 years 198 . In a cohort of individuals from South Korea's Korean Sarcopenic Obesity Study, an ongoing epidemiological, prospective cohort of healthy volunteers aged 20-80 years, prevalence of sarcopenic obesity ranged from 1.3-15.4% in men to 0.8-22.3% in women 199 . The prevalence of low muscle strength with obesity is less clear. Data from the InCHIANTI study noted rates of 3.2-8.7% using the low knee extensor strength with either high BMI or waist circumferrence 200 . Investigators from the Cardiovascular Health Study used low grip strength and high waist circumference to define low muscle strength and obesity. Rates approached 11.1% 201 , while data from FNIH classified 4.1% of men and 14.0% of women as having sarcopenic obesity using high BMI and low grip strength as measures of obesity and low muscle strength, respectively 202 . Overlap using different .
Consequences of sarcopenic obesity
Cross-sectional and longitudinal studies are subject to the same definitional challenges as prevalence studies. Despite the crucial need for a consensus definition, here we describe the clinical importance of sarcopenic obesity.
Disability or impairments. Richard Baumgartner and colleagues were the first to characterize the association between sarcopenia (as defined by appendicular lean mass) and percent body fat on incident disability 191 . In their analysis, when compared with a healthy body composition, sarcopenic obesity was associated with a relative risk of incident disability over 8 years that was 2.63 (95% CI 1.19-5.85). In addition, when compared with a healthy body composition, a combination of obesity, as defined by percentage of body fat, with low muscle mass represented odds ratios of difficulty ascending and descending stairs that were 2.60 and 2.35 higher, respectively 203 . The Concord Health and Aging project 204 used the FNIH criteria for sarcopenia with elevated body fat to evaluate frailty and reported that sarcopenic obesity resulted in an increased risk of frailty (OR 2.00, 95% CI 1.42-2.82), activity of daily living disability (OR 1.58, 95% CI 1.12-2.24) and instrumental activity of daily living disability (OR 1.36, 95% CI 1.05-1.76). The above results contrast with an earlier cross-sectional study that defined sarcopenic obesity by low muscle mass and elevated body fat and did not demonstrate differences in disability compared with controls 205 . Another group used DXA to assess body mass and its relationship with physical capacity and found mixed results
188
. Data from the Quebec Longitudinal Study applied definitions of sarcopenic obesity comprising Baumgarter's definitions of sarcopenia and obesity as defined by body fat 191 and found global physical capacity scores were no different between obese groups (sarcopenia versus non-sarcopenia (P = 0.14 in men and P = 0.19 in women)), but lower scores were observed than with the non-sarcopenic non-obese group (P < 0.05) 188 . Women with sarcopenia alone had higher scores than people with obesity without sarcopenia and than individuals with obesity and sarcopenia (P < 0.01).
Muscle strength is a stronger predictor of long-term functional decline than muscle mass 206 . Data from the Osteoarthritis Initiative showed that a combination of low knee extensor strength with high BMI was associated with reduced gait speed and reduced Late-Life Function and Disability Index and Short Form-12 scores 207 , which indicate a lower degree of physical function 208 and decreased self-reported health status 209 . Low handgrip strength and elevated BMI were strongly associated with an increased risk of functional decline 210 . In addition, data from the UK Biobank study found an association between high BMI, low grip strength and reduced long-term physical activity 211 . Data from the InCHIANTI study showed that mobility disability trajectories and gait speed over 6 years were steepest in individuals with obesity as defined by BMI and low muscle strength 200 . An increase in mobility disability and risk of hospitalization (OR 2.10, 95% CI 1.14-3.88) was associated with low muscle strength and abdominal obesity in an 11-year follow-up study (OR 1.36, 95% CI 1.04-1.78). High BMI and low muscle strength were related to limitation in mobility at 2-year follow-up (OR 3.88, 95% CI 1.08-13.91) 212 . In another study, abdominal visceral fat and quadriceps muscle area served as markers for central obesity and sarcopenia, respectively, and were associated with postural instability 213 .
Metabolic impairments.
A study from the South Korean NHANES conducted an evaluation of sarcopenia (as defined by muscle mass) with obesity (as defined by a BMI ≥25 kg/m 2 ). The authors reported that individuals with sarcopenic obesity were at an increased risk of dyslipidaemia (OR 2.82, 95% CI 1.76-4.51) 214 and had significant positive associations with insulin resistance as defined by HOMA scores and triglycerides 215 . In another study, low handgrip strength and high waist circumference and/or BMI were significantly associated with elevated levels of IL-6, C-reactive protein and IL-1 (ref.
57
) but conflicted with results using the FNIH criteria to define low lean mass 216 . By contrast, low muscle strength (as defined by the FNIH criteria) with an elevated BMI was not associated with differences in metabolic components among groups of postmenopausal women aged 55-75 years 217 .
Comorbidities. Individuals with sarcopenic obesity have a higher risk (OR 3.51, 95% CI 2.15-5.75) of radiographic knee osteoarthritis 218 than individuals in the non-sarcopenic obesity group. One study reported that risk of falling was highest in individuals with low muscle mass and/or strength with obesity as defined by percentage of body fat 219 , but spine and total BMD were lower in individuals who were sarcopenic obese and dynapenic obese than in individuals with obesity alone 220 . A study that evaluated participants over 6 years reported that the combination of obesity as defined by BMI and low handgrip strength suggested an increased risk of type 2 diabetes mellitus (OR 3.57, 95% CI 2.04-6.24), an association that was not observed with cardiovascular disease 221 . The rate of depression has been reported as being highest in patients with sarcopenic obesity (defined as low handgrip strength and obesity defined by BMI) (OR 1.79, 95% CI 1.10-2.89) over 4 years 222 compared with non-obese individuals in the highest tertile of grip strength. These data were confirmed in another study that defined sarcopenic obesity as low muscle mass or muscle strength, with obesity defined by percentage of body fat 223 . Individuals with low muscle mass and high waist circumference had worse psychological health and higher stress than individuals with normal muscle mass and normal waist circumference. Finally, an area of interest for researchers now is the role of sarcopenic obesity in cancer 224 , which further demonstrates its relationship with adverse health events.
Mortality. Epidemiological studies investigating the relationship between sarcopenic obesity and mortality have reported conflicting results 198, 204, 221, [225] [226] [227] [228] . A longitudinal study from 2017 demonstrated small differences in all-cause mortality between obesity as defined by both BMI and low muscle strength and low muscle strength alone 229 . Others showed that mortality was significantly elevated in people with sarcopenic obesity, which was defined using mid-arm circumference (HR 1.46, 95% CI 1.23-1.73) and muscle strength with waist circumference (HR 1.23, 95% CI 1.09-1.38) 230 . Sarcopenic obesity (defined by muscle mass assessed by bioelectrical impedance and percentage of body fat) was associated with an increased mortality (HR 1.29, 95% CI 1.03-1.60) 230 . Muscle strength also affects mortality independent of muscle mass. Investigators from the Health, Aging and Body Composition study reported that low quadriceps strength was associated with increased mortality 231 . Similar results were reported in another study that showed that reduced leg isometric strength and increased waist circumference were associated with increased mortality 232 (HR 2.46, 95% CI 1.34-4.52). These results were further corroborated in the MiniFinland Health Examination Study, which also showed that reduced muscle strength is associated with increased mortality (HR 1.30, 95% CI 1.09-1.54) 228 . Cutoffs specific to individuals from South Korea predicted higher mortality risk than the FNIH cut-off 233 . Finally, a recent meta-analysis found that mortality was highest in patients with sarcopenic obesity (HR 1.24, 95% CI 1.12-1.37) compared with healthy individuals, but the authors acknowledged that they had used multiple definitions of sarcopenic obesity in their study 230 .
Quality of life.
Few studies have evaluated the effect of sarcopenic obesity on quality of life. Sarcopenic obesity (as defined by low appendicular lean mass normalized for height 2 and increased BMI) was associated with unfavourable scores on the Medical Outcomes Survey 234 . Another study reported no differences in Short Form-36 scores, which provide a measure of quality of life 235 , between individuals with obesity and low handgrip strength and individuals with normal indices 236 . The EuroQOL score was dependent on cardiovascular fitness rather than sarcopenic obesity 237 . Future studies need to focus on health-related quality of life and patient-reported outcomes in sarcopenic obesity before we are able to draw firm conclusions.
Institutionalization and health-care utilization. Few studies, and no known longitudinal studies, have evaluated the relationship between sarcopenic obesity and institutionalization. Peggy Cawthon and colleagues 238 reported that neither sarcopenia nor the components that define weakness increased the risk of hospitalization or short-term nursing facility stay. A population-based cohort study that defined sarcopenia using the EWGSOP criteria found an increased incidence of long-term care certification in patients with sarcopenia 239 . Low muscle mass or strength is causally associated with long-term care placement. The relationship with obesity is clearer, whereby an elevated BMI is associated with admission to a nursing home 240 . Midlife obesity also increases the risk of long-term care placement 241 , an association that persists in older adults with obesity 242 .
Treatments for sarcopenic obesity Lifestyle interventions, including calorie restriction and physical activity, are hallmarks of treating sarcopenic obesity (TAble 2) . Few clinical trials specifically focus on sarcopenic obesity 243 ; however, intentional weight loss in older adults improves morbidity and physical function 186 . Following a meta-analysis of randomized trials of adults with obesity aged ≥55 years, which had follow-up times of ≥4 years, investigators reported a 16% reduction in mortality (95% CI 0.71-0.99) 243 . In the United States, while Medicare covers weight loss therapy 244 , no major societies outline targeted therapies for sarcopenic obesity 187, 245 . Dennis Villareal's work best corresponds to participants with sarcopenic obesity as defined by obesity with evidence of physical frailty 246, 247 . In this cohort of patients, weight loss alone or exercise alone improved physical function; however, a combination of weight loss and regular exercise improved physical function and ameliorated frailty more than either intervention alone 246 . Moreover, another study reported that weight loss plus combined aerobic and resistance exercise was the most effective method for improving functional status of adults aged 65 years and older with obesity 247 ( fig. 3) . Hung-Ting Chen and colleagues 248 evaluated four groups of individuals with sarcopenic obesity according to different exercise interventions (aerobic, resistance, combined aerobic and resistance), and controls who were prohibited from engaging in exercise, and demonstrated that individuals in the resistance training group had the greatest improvements in strength. . The source of protein, timing of intake 257 and specific amino acid constituents can also be factors in increasing muscle mass and strength. High protein intake (1.2 g of protein per kg per day) during weight loss might eliminate the beneficial effect of weight loss on insulin sensitivity in skeletal muscle 258 . Distributing protein intake throughout the day 259 or pulse feeding at main meals 260 could be beneficial for the stimulation of muscle protein synthesis in patients with sarcopenic obesity.
The PROT-Age group recommends 1.0-1.1 g/kg protein per day in divided doses, acknowledging that a 'one size fits all protein recommendation' fails to account for the complex physiological changes of ageing 71 . Generally, 25.0-30.0 g of protein containing 2.5-2.8 g of leucine can slow frailty 261, 262 . Early pilot studies demonstrate that meals enhanced with protein and coupled with a weight loss intervention improve physical function 263 . For example, a highprotein diet in conjunction with resistance training preserved appendicular lean mass during weight loss 264 . In a pilot study, participants with sarcopenic obesity undergoing a weight loss programme augmented by a high-protein diet showed improvements in muscle strength and Short Form-36 scores (ref. 265 ). We need further evidence to support the effect of supplemental protein on functional outcomes in patients with sarcopenic obesity [266] [267] [268] . High-protein diets consisting of 1.0-1.2 g per kg per day should be prescribed with caution to prevent renal dysfunction 269 as evidenced by observational data [270] [271] [272] , as higher doses have recently demonstrated no changes in lean mass 273 . We recommend the importance of ensuring adequate protein intake in countering weight loss-induced sarcopenia in individuals with sarcopenic obesity participating in programmes. Careful medical monitoring and dietary planning are required when optimizing protein intake while limiting calorie restriction, and this often needs to be administered under the auspices of a registered dietician with expertise in this population. The challenges in limiting calories are recognized, and hence we believe that alternative approaches are crucially needed to augment muscle mass and strength. and strength (measured as total one repetition maximum (that is, the total of the maximum weight a participant can lift, in one attempt, in the bicep curl, bench press, seated row , knee extension, knee flexion and leg press)) (part d). Scores on the PPT were used as an objective measure of frailty (primary outcome), and scores on the FSQ were used as a subjective measure of frailty. Percentage changes are presented as least-squares-adjusted means; T bars indicate standard errors. *P < 0.05 for the comparison with the control group. **P < 0.05 for the comparison with the aerobic group. ***P < 0.05 for the comparison with the resistance group. Resistance training and aerobic exercise. Several professional societies 3, 187, 245, 274 recommend that all older adults engage in at least 150 min per week of moderate to vigorous aerobic exercise, with two sessions of resistance exercises consisting of strength training, flexibility and balance. Aerobic exercise and resistance training are safe, even in patients who are at a high risk of falling 275 . Aerobic exercise improves cardiorespiratory fitness and has beneficial effects on mortality [276] [277] [278] . Even minimal resistance exercise improves muscle strength and mass 279, 280 , and progressive resistance exercises counter sarcopenia by increasing strength. As with any exercise programme, clinical consultation and medical clearance is advised.
A Cochrane review reporting physical outcomes of progressive resistance exercises for older people identified 33 trials that significantly improved physical abilities (standardized mean difference 0.14, 95% CI 0.05-0.22) in 2,172 participants, with improvements in muscle strength (standardized mean difference 0.84, 95% CI 0.67-1.00) in 73 trials 281 (3,059 participants). The LIFE study 282 , a structured, moderate-intensity physical activity programme, demonstrated reduced persistent mobility disability (HR 0.72, 95% CI 0.57-0.91) compared with a health education programme. Evaluation of four groups of men and women aged 60-75 years with sarcopenia demonstrated that 2 days of high-resistance concentric exercise with one bout of low-resistance exercise increased muscle expression of pro-inflammatory cytokine receptors, maximized muscle mass and total lean mass and improved knee extension 283 . A secondary subset analysis of the LIFE pilot study found that the short physical performance battery -an objective assessment tool for the evaluation of lower extremity function (higher score equals better function) 284 -of patients with sarcopenia improved from 7.4 to 8.7 when compared with the successful ageing group 285 . Although the LIFE study is considered a standard for physical activity in older adults 282 , we acknowledge its lack of evidence in sarcopenic obesity and the lack of power in this pilot trial.
High-intensity resistance training combined with short resting intervals improves body composition, muscle and functional performance in men aged 68 ± 4.1 years 286 . High-speed resistance training over 12 weeks induced greater improvements in muscle power and functional capacity than low-speed training 287 . In this study of 60 women of Hispanic descent aged over 60 years, high-speed training consisted of individuals performing exercises as fast as possible (1 second or less) and was compared with low-speed resistance training (3 seconds). The authors of this study also demonstrated that two versus three training sessions per week for 12 weeks of high-speed resistance training were equally effective for improving physical performance and quality of life 288 . High-velocity knee extension training at 240° of movement per second increases the expression of MYH6 and MYH9 mRNA and improves muscle enhancement 138 . The effect of power training (moving resistance at higher speed) on function requires further investigation 289, 290 . A pilot study of patients with sarcopenic obesity (defined using EWGSOP criteria for sarcopenia and BMI for obesity) were randomized to a strength and hypertrophy group or a high-speed circuit group for 15 weeks 289 . High-speed circuit training was associated with nonsignificant improvements between groups in short performance physical battery (mean difference 1.1, 95% CI -0.1 to 2.4; P = 0.08) and power (mean difference 158 W, 95% CI 2-315; P = 0.01). We note that while these trials enrolled patients with sarcopenic obesity in each arm, they are small, short-term studies.
Other exercise therapies, including tai chi or yoga, could potentially be beneficial; however, to our knowledge, no studies have evaluated these modalities in sarcopenic obesity. Tai chi and The Otago Exercise Programme (a home-based balance and strength fall prevention programme) have been shown to be effective at preventing falls and improving physical function, mobility and functional measures of lower extremity strength in older adults 291 . A meta-analysis of 18 trials (n = 3,824), including study participants greater than 65 years who participated in tai chi for a minimum of 4 weeks (range 1-12 months) 1-3 times per week, demonstrated a reduction in falls of 20% (relative risk (RR) 0.8, 95% CI 0.72-0.88) 292 . In addition, yoga has been shown to improve mobility in participants 60 years of age and older, with no restriction on their characteristics, whose follow-up ranged from 8 to 24 weeks (total duration 8-36 hours of yoga) 293 . A meta-analysis of 28 studies demonstrated a positive effect of aquatic exercises on physical functioning (RR 0.70, 95% CI 0.48-0.92) compared with no training (control group) 294 . Furthermore, the data suggested that aquatic exercises are as effective as land-based exercises (standardized mean difference 0.39, 95% CI 0.12-0.66). Finally, while training until failure might be an approach for muscle strengthening and endurance 295 , we generally recommend exercising until fatigue rather than failure, as exercising until failure can increase the risk of musculoskeletal injury.
We advocate individualized exercise treatment for patients with sarcopenic obesity because of the associated medical comorbidity and disability. As previously described, the exercise programme 296 should begin at a fairly low-to-moderate intensity, duration and frequency to minimize injury and maximize adherence; this approach progressively induces exercise adaptations 246, 247 . Aerobic activity should target ~65% of the peak heart rate, aiming to reach 70-85% of peak heart rate over the duration of the exercise regimen. Resistance activities, on the other hand, should focus on 1-2 sets of 8-12 repetitions at ~65% of one repetition maximum, which is defined as the maximal amount of force a person generates in a single repetition, with the aim of advancing to a goal of 2-3 sets of 75% of one repetition maximum over time. These activities are recommended even for frail, older adults 246, 247 .
Calorie restriction and physical activity. A trial of older adults with obesity 247 consisted of a hypocaloric diet with an energy deficit of 500-750 kcal per day on average, 1 g high-quality protein, plus either 60 min of progressive aerobic exercise and resistance training or 75-90 min of both aerobic exercise and resistance training, three times a week. The findings demonstrated increases in physical performance test scores (higher score equals higher level of function), more so in the combined aerobic and resistance exercise group (27.9 to 33.4 points (21% increase)) than in the aerobic (29.3 to 33.2 points (14% increase)) or resistance group (28.8 to 32.7 points (14% increase)) alone. Other activities for weight loss therapy in older adults reflect similar components and outcomes and have produced similar findings 250, 297 . There are few multicomponent studies in patients with sarcopenic obesity. A meta-analysis showed that aerobic exercise and resistance were useful tools to preserve fatfree mass in adults aged ≥50 years who were engaged in a moderate energy restriction-induced weight loss programme 298 . Increased muscle mass and reduced total and visceral fat over an 8-week intervention were observed in predominantly female individuals, whose mean age was 69 years, with sarcopenic obesity engaged in resistance training 248 . A resistance programme of participants fulfilling the EWGSOP criteria for sarcopenia and obesity as defined by percentage body fat demonstrated reduced rates of sarcopenia and improved physical function following three training sessions weekly over a 12-week period compared with a control group receiving no intervention 297 . A combined treatment of diet and exercise improved physical function in frail older men with obesity aged ≥65 years for 1 year, despite resulting in a reduction in oestradiol levels and only a modest increase in testosterone levels 299 .
Combining both diet and exercise can positively improve adipose markers of adiponectin and significantly reduce leptin levels. In response to a 6-month randomized diet and exercise intervention, levels of C-reactive protein and IL-6 decreased in older adults (age ≥65 years) with obesity (BMI ≥30 kg/m 2 ) compared with controls (−2.5 versus 0.8 mg/l (P < 0.05) and −2.4 versus 1.6 pg/ml (P < 0.05), respectively) 300 . Yet, the positive effects on circulating cytokines, adiponectin and TNF were due to diet and not exercise 301 , which is consistent with the direct effect of exercise on or within muscle not being reflected in the circulation 133, 134 . A study that investigated the effect of diet or diet and exercise interventions in individuals aged 50-79 years with overweight or obesity reported that levels of adiponectin increased in individuals with overweight or obesity compared with controls (diet resulted in 9.5% increase in adiponectin (P < 0.001), and diet and exercise resulted in a 6.6% increase in adiponectin (P < 0.001)). Furthermore, levels of leptin in individuals with obesity or overweight decreased by 27.1% in the diet group and 40.1% in the diet and exercise group 302 . Investigators in the LIFE pilot study reported that individuals in the physical activity group had reductions in IL-8 but no differences in other inflammatory markers 303 . A 12-week aerobic exercise regime in combination with a low glycaemic index diet or high glycaemic index diet resulted in reductions in leptin levels in two groups of participants who had elevated levels of adiponectin, suggesting that the reductions in leptin were a result of exercise training and independent of dietary glycaemic index 304 . Another study reported that in postmenopausal women with overweight or obesity, adding aerobic activity to calorie restriction increased serum concentrations of adiponectin (6.9 μg/ml for individuals in the group without aerobic activity versus 8.5 μg/ml for individuals in the group with aerobic activity (P < 0.001)) 305 . Levels of adiponectin were also elevated following a multicomponent, randomized lifestyle intervention study that investigated the mRNA expression of adiponectin and its receptor in skeletal muscle in adults with impaired glucose tolerance who were aged ≥60 years and had a BMI of 30-40 kg/m 2 (ref. 306 ). These data suggest that improved insulin sensitivity is due, in part, to the distribution of adiponectin across various tissues and an upregulation in the expression of its receptor. Other conflicting data suggest that in patients with knee osteoarthritis, weight training combined with walking three times a week for 1 hour does not have any significant effect on levels of TNF, IL-6 or C-reactive protein 307 . The addition of weight loss of 0.3 kg per week for 6 months to physical activity in older community-dwelling adults with obesity or overweight results in a greater reduction in serum levels of leptin and IL-6 than either physical activity alone or a successful ageing health education intervention 308 .
Risks of weight loss in older adults
Energy restriction with a hypocaloric diet with or without exercise results in the loss of approximately one-quarter of lean mass per unit weight, which could worsen sarcopenia and osteopenia 154 . A total of 33 intervention studies lasting 8-24 weeks reported that unopposed calorie restriction without resistance training leads to the loss of muscle mass and loss of handgrip strength of up to 4.6% and 1.7 kg, respectively 309 . Unopposed diet therapy without exercise in older frail adults ≥65 years with obesity (BMI ≥30 kg/m 2 ) led to a marked loss of lean mass at 6 months and 1 year (−3.5 kg and −3.2 kg, respectively) compared with the diet and exercise group, where the loss of lean mass was partially mitigated (−1.7 kg and −1.8 kg, respectively) 246 . In the Look AHEAD trial, total skeletal mass decreased in both of the intensive lifestyle groups and in the diabetes support and education group (−1.4 kg; P < 0.001). The researchers reported that patients in the intervention group regained appendicular lean mass during the second year and that weight loss was 5.2 kg less in the intervention group than in participants in the control group, whose weight did not markedly change after the second year 310 . A review of 52 studies reported that loss of fat-free mass as a proportion of overall weight was attenuated after combining exercise with calorie restriction 298 . Weight loss in younger adults (age 45-65 years) led to loss of lean mass after calorie restriction (4% reduction in lean mass; P < 0.0001), which was partially lessened by augmentation with aerobic activity (2% reduction in lean mass in participants who had augmented weight loss with aerobic activity; P = 0.05) 311 . One study evaluated the effectiveness of low-fat diets versus carbohydraterestricted diets with or without progressive resistance exercise on fat-free mass in 42 men with the metabolic syndrome whose age was 59 ± 7 years. Percent weight loss from appendicular lean mass dropped markedly more in the low-fat and no exercise group than in the other groups, suggesting that this intervention has a detrimental effect on appendicular lean mass 312 .
Obesity is inversely related to BMD and fractures 313 but might increase the fracture risk through bone quality 314, 315 or frailty 132,316 independent of BMD. Adipose tissue has been shown to be inversely associated with bone material strength and positively associated with cortical porosity, indicating an adverse effect of adipose tissue on bone microstructure 317 . Calorie restriction alters bone metabolism, resulting in the loss of BMD in the hip without effects on lumbar spine 318 , even after a 4-month restriction 319 . Increases in bone markers such as osteocalcin and of carboxy-terminal telopeptide (C-telopeptide) and N-terminal telopeptide (N-telopeptide) of type I collagen were observed. Levels of osteocalcin were increased in the diet-only group (36 ± 11.6%), yet its levels were no different than baseline in individuals on diet coupled with exercise; increased differences were reported in the disposition index (an index of insulin secretion after correction for insulin resistance) in the diet-exercise group (92.4 ± 11.4%) compared with the diet-only group (61.9 ± 15.3%) at 12 months 320 . Loss of BMD in older adults with obesity seems to continue during long-term lifestyle change in the opposite direction to the weight changes 321 . These findings suggest that BMD and markers of bone turnover following long-term calorie restriction show larger changes in patients than in healthy control participants advised to continue their current diet 322 . In one study, the authors reported that trabecular bone microarchitecture was no different in calorierestricted participants (~35% less calories than controls) than in middle-aged individuals eating a Western diet 323 . Furthermore, trabecular geometry, cortical geometry and strength were no different in individuals undergoing intentional weight loss through calorie restriction or weight maintenance for 6 months 324 , which suggests that calorie restriction has protective effects on bone quality. However, 2017 data from the Look AHEAD trial showed that long-term intentional weight loss was associated with a 39% increased risk of fragility fractures 325 . Very-low energy or protein-sparing diets to induce rapid weight loss are not recommended owing to potential loss of muscle mass, strength and bone and risks of dramatic fluid, electrolyte and water shifts owing to protein shifts; however, a preliminary, short-term study in a population of individuals ≥65 years of age suggests potential benefits 326 . Studies emphasize exercise training during calorie restriction to prevent an increase in bone turnover 327 and an increase in serum levels of sclerostin 328 , thus minimizing bone loss. Whether weight loss and exercise lower overall risk of falls and fractures despite the decline in BMD is unknown, suggesting the need for formal evaluation in future studies.
Supplementation with calcium and vitamin D.
Conventional strategies to minimize the effect of weight loss on bone metabolism, including up to 1,200 mg supplemental calcium per day and 800-1,000 international units (IU) per day of vitamin D 3 , are needed to minimize the risk of weight loss-induced BMD reduction 329 . Oral calcium should be coupled with vitamin D to mitigate the potential risks of unopposed supplementation 330 . Supplementing vitamin D in patients with sarcopenic obesity can potentially influence and improve muscle function 331 and proximal muscle weakness 332 through the actions of vitamin D metabolites 333 . Vitamin D deficiency is associated with an increased risk of falls and fractures, and reduced muscle mass and strength [334] [335] [336] [337] [338] , independent of obesity. We agree with the American Geriatrics Society recommendation of 1,000 IU of vitamin D 3 per day with calcium among non-institutionalized adults aged ≥65 years 334 , to maintain serum levels of vitamin D at ≥30 ng/ml.
Future directions and emerging therapies
We anticipate that a deeper understanding of sarcopenic obesity will emerge over the next decade, which will ultimately bridge the divide between clinical practice and research. Here, we outline the major gaps of knowledge and advancements needed to further the field (bOx 1).
Harmonizing a definition. The most notable barrier to advancing the science in targeting this condition is the lack of a consistent definition for sarcopenic obesity. While the criteria for identifying and classifying subcutaneous or visceral adiposity are somewhat consistent, major progress is needed regarding the definition of sarcopenia. Advancing our understanding of the relative contributions of strength and muscle mass -as well as their differences -might help. The introduction in 2016 of an International Classification of Diseases 10 code for sarcopenia (M62.84) will permit clinical recognition and promote its diagnosis, classification and drug development 339, 340 . Different populations, ethnicities and sexes require specific diagnostic thresholds; therefore, integrating highly accurate body composition measures into clinical settings will encourage clinical identification of sarcopenic obesity. The disparate classification has impeded progress in this field.
Integrating methods for analysing body composition into clinical practice. To promote the translation of methods for assessing body composition, including CT, MRI and DXA, into routine care, we acknowledge the need to remove regulatory and operational obstacles, particularly in the United States. For instance, DXA is routinely performed for screening and assessment of osteoporosis and is generally covered by insurance for this indication 341 . Older adults often receive gold standard imaging, which can accurately ascertain muscle and fat content, for indications other than sarcopenic obesity, such as abdominal pain or back pain 342, 343 . Assessing muscle strength (using handgrip dynamometry) and muscle mass (using DXA, bioelectrical impedance or other modalities) can fill a clinical gap in identifying sarcopenic obesity. Widespread availability of DXA even in low-resource areas 344 permits this evaluation. Future studies should focus on dissemination and implementation strategies of using such diagnostics.
Epidemiology and clinical outcomes. Further work is required to elucidate the descriptive epidemiology of sarcopenic obesity regarding important outcomes beyond weight loss, comorbidity and mortality. Though experts currently debate a unifying definition, one will ultimately become accepted, standardized and implemented.
Until then, useful and cost-effective measures, including grip strength, gait speed, the short performance physical battery and/or bioelectrical impedance or DXA, should continue to be used in clinical and research arenas [345] [346] [347] . Focusing on patient-centred outcomes, including physical function and quality of life, is important. Additional trials in sarcopenic obesity can clarify the mechanisms underlying interactions between fat, muscle and bone that explain alterations in short-term and long-term outcomes. Improved characterization of biological signalling will permit full comprehension of the differences between sarcopenia and sarcopenic obesity. The association of resource and cost data in health systems and third-party payers (insurers) will escalate the importance of sarcopenic obesity.
Dietary composition and restriction.
No specific interventions have tested diets for the treatment of sarcopenic obesity. While diets should be individualized, the composition of carbohydrates, fats and protein have differed in clinical trials. Adjusting these components might differentially affect muscle mass, strength and weight. Research should distinguish appropriate diets, the type of protein to administer (such as whey or casein) and potentially the timing of intake in relation to exercise, as well as whether recommendations should be based on ideal or total body weight. The specific composition of essential amino acids (for example, leucine or creatine) and vitamin D supplementation requires structured interventions to ascertain dosing and monitoring. For instance, leucine-rich protein can activate metabolic pathways involved in testosterone and IGF1 homeostasis [348] [349] [350] [351] . Such elements will allow tailored dietary interventions.
Exercise and combined interventions. While aerobic and resistance exercises are core components in the treatment of sarcopenic obesity, the specific frequency, intensity, time and types (aerobic, resistance or both) should be considered. The relationship of resistance exercises with respect to dietary composition requires evaluation. Longitudinal studies should verify whether weight loss plus combined aerobic and resistance training prolongs physical independence in sarcopenic obesity. Such studies might translate to older adults who have access to health membership benefits in community-based exercise centres 352 . Assessing aquatic therapies [353] [354] [355] or tai chi 356 , in isolation or in tandem with other types of physical activities, might prove useful for treating patients with sarcopenic obesity. The addition of pharmacotherapy, such as testosterone supplementation, to progressive resistance training augmented the improvements in body composition, including reduced fat mass and improved lean mass 357 . However, whether or not physical activity should be combined with novel and promising treatments requires systematic and further investigation. Periodization strategies. Periodization, which is a systematic variation in physical training specificity, intensity and volume within periods, has emerged as a potential strategy to improve muscle performance 358 . Periodization is typically used in sports programmes aiming to achieve peak physical performance while minimizing overtraining risk. Linear periodization reduces training volume while increasing training intensity or load between cycles 359 . Periodized resistance training in older adults demonstrated equal efficacy in physical function and physiological outcomes when compared with non-periodized resistance training 360 . In patients with sarcopenic obesity (defined using handgrip strength and BMI), no differences were observed in strength, power or short performance physical battery following a 10-week periodization strategy of strength and endurance training with concentric and eccentric movements 290 . Preliminary studies indicate that periodization results in increases in serum levels of irisin and decreases in IL-1β 361 . Leptin might also be reduced further with periodized resistance training 362 . While periodization could feasibly be prescribed in sedentary or frail older adults to improve physical function, it is premature to endorse this training as superior to non-periodized training 358 . Longer-term investigations in older populations with sarcopenic obesity are needed.
Box 1 | Emerging therapies in sarcopenic obesity
Anamorelin A ghrelin analogue used in cancer cachexia that could promote appetite and enhance lean mass with anti-inflammatory and anabolic properties.
Bariatric surgery
The safety and efficacy of different procedures (Roux-en-Y, gastric band and gastric sleeve) are currently unknown but can be considered in carefully selected older adults aged 65 years and older.
Mesenchymal stem cells
Shared precursors of muscle, bone and cartilage that hold promise in the regeneration of muscle tissue. Barriers exist but these cells may play a promising role in the future management of sarcopenia.
Myostatin inhibitors
A treatment type with biological plausibility for improving physical function by enhancing skeletal muscle growth development. This class of therapy can directly inhibit muscle loss, with data suggesting improvements in physical function in patients with cancer.
Neuromuscular activation
Whole-body vibration therapy (using electrical stimuli) or tai chi can enhance muscle contraction efficiency and function.
Periodization strategies
Systematic variation in training specificity, intensity and volume used in sports programmes to achieve peak physical performance. may be feasibly prescribed in sedentary, frail, older adults to improve function but it is premature to endorse these strategies.
Testosterone and selective androgen receptor modulators
Important regulators of body composition that increase muscle and bone mass by increasing insulin-like growth factor 1 (IGF1) and decreasing inflammatory markers. Data on their impact on muscle strength and function are conflicting. Selective androgen receptor modulators (that is, enobosarm) preferentially target androgen receptors on muscle and bone, sparing the androgenic impact elsewhere in the body. early efficacy studies demonstrate improved lean mass and function in patients with cancer.
Weight loss therapies
Anti-obesity medications (liraglutide, lorcaserin, phentermine, topiramate, bupropion and orlistat) are approved for use in non-geriatric populations with weight loss as an indication. Their use is restricted to off-label use for weight loss, and few data exist on their safety and efficacy in this population.
Vitamin K
Inhibits bone resorption and osteoclast formation and may be helpful in mitigating bone loss following intentional weight loss. Supplementation may increase bone resorption markers, although conflictive data exist on its effect on BmD and fractures.
Whole-body vibration therapy. Whole-body vibration therapy is a novel therapy that could increase muscle contraction efficiency and function with similar efficacy to resistance training, though data on its efficacy are mixed. This safe and convenient technique is associated with a low risk of injury 363, 364 . Whole-body vibration therapy uses the transmission of mechanical stimuli through the person's body 365, 366 to activate the primary ends of muscle spindles, which leads to neuromuscular activation [367] [368] [369] . The participant stands on a vibrating platform where electrical signals are delivered through the body, and thus primary endings of muscle spindles are activated.
Hengting Chen and colleagues 370 identified 10 randomized trials of whole-body vibration therapy showing its usefulness in younger adults (difference (d) = 0.35 (95% CI 0.05-0.64; P = 0.02)), but this usefulness was not seen in older adults (d = −0.04 (95% CI −0.28 to 0.21; P = 0.78)). The review included heterogeneous studies using different methodologies, training and vibration characteristics. Separately, Ricky Lau and colleagues 371 reviewed 13 trials of older adults and found significant treatment effects on knee extension dynamic strength (d = 0.63; P = 0.006), isometric strength (d = 0.57; P = 0.003) and functional measures such as sit-to-stand (d = 0.72; P < 0.001). Whole-body vibration therapy was as efficient as a fitness programme at increasing knee extension and lower leg muscle mass in non-institutionalized men aged 60-80 years old 372 and improved quality of life and functional measures 373 . Summative effects of the combination of wholebody vibration therapy and resistance exercises [374] [375] [376] [377] or of whole-body vibration therapy and vitamin D 367 are mixed. Others hypothesize that pathways contributing to weight loss as a result of whole-body vibration therapy could inhibit adipogenesis, increase energy expenditure and reduce muscle mass 378 . Augmenting existing squatting exercises with whole-body vibration therapy failed to improve muscle mass in younger men aged 18-30 years 379 . Future research should focus on type, frequency and duration of treatment 380 .
Weight loss medications. None of the six FDA-approved medications for weight loss are approved for use in older adults aged over 65 years, and few have been evaluated in terms of changes in body composition. In nine older adults prescribed liraglutide, a weight decrease of 2.0 kg (−1.5 kg fat mass and −0.9% android fat) was observed, with a marginal improvement of 0.03 kg/m 2 in skeletal muscle index (absolute muscle mass normalized by height squared) 381 . Lorcaserin leads to more fat loss than placebo in patients with diabetes mellitus (−12.1% versus −5.9%; P = 0.008) and more trunk obesity (3.65% versus −0.36%). When compared with controls, patients treated with lorcaserin had greater fat mass loss than lean mass loss 382 . Topiramate negatively affects BMD 383 but might not affect lean mass 384, 385 . Phentermine minimally alters lean mass 386 . Bupropion can blunt olanzapine-associated weight gain without affecting bone metabolism 387 and in combination with naltrexone can lead to a reduction in fat mass without altering lean mass 388 . Orlistat promotes the weight loss via fat and visceral adipose tissue loss but minimally changes lean mass [389] [390] [391] . In carefully selected individuals, industry-sponsored trials should evaluate these agents in both older adults with obesity and patients with sarcopenic obesity.
Bariatric surgery. Bariatric surgery improves weight and metabolic outcomes and reduces mortality. In carefully selected patients, this could be considered a treatment for sarcopenic obesity in older adults ≥65 years 392 . Its safety and efficacy in sarcopenic obesity is unknown other than one study that evaluated the influence of sarcopenic obesity on gastric bypass and sleeve gastrectomy results 393 . The population of participants had a mean age of 44 years, and no documented differences were observed in weight loss results or comorbidity resolution. Bariatric surgery leads to loss of fat mass 394 , alters gut hormones 395 and can exacerbate weight loss-induced sarcopenia [396] [397] [398] and osteoporosis [399] [400] [401] [402] . Carefully designed studies are needed before promoting this intervention.
Testosterone. Obesity negatively affects serum levels of testosterone and disrupts the actions of testosterone by increasing its aromatization to oestrogen 403 and downregulating follicle-stimulating hormone and luteinizing hormone 404 , thus exacerbating hypogonadotropic hypogonadism. Testosterone is an important regulator of body composition with ageing, as it increases muscle and bone mass, increases IGF1 levels, decreases inflammatory markers 405 and alters biomarkers of bone turnover in adults with hypogonadism. Testosterone deficiency can impair muscle adaptation to exercise owing to reduced expression of IGF1 and increased inflammatory cytokines. However, reductions in TNF and IL-6 observed in older men with hypogonadism can be reversed following testosterone treatment 406 . Supplementation with testosterone promotes IGF1 mRNA and protein expression, leading to increased lean mass through increased muscle protein synthesis 52 . Increases in IGF1 following testosterone administration might improve muscle mass and strength enhanced by exercise 52, 56, 406 , and in men over 60 years with low testosterone, gains in lean mass following testosterone supplementation ranged from 1.6 kg to 6.20 kg (ref. 407 ).
Androgen therapy also reduces fat mass (−1.78%). Therapy with testosterone and GH in older men aged 65-80 years with normal testosterone levels resulted in greater improvements in lean mass with both treatments than with either alone 56, 408 . In select older men over the age of 60 years with testosterone deficiency and frailty, body composition and quality of life improved following supplementation with testosterone [409] [410] [411] . Three years of testosterone administration in patients with low levels of testosterone resulted in an increase in lean mass (0.9 kg, 95% CI 0.5-1.4; P < 0.001) 412 . Testosterone deficiency and treatment in older men have been reviewed elsewere 413 . There are conflicting data on the effect of testosterone supplementation on muscle strength and function 50, 51, 357, 414 . In the 'Testosterone Trials' , treatment with testosterone improved participants' results in the 6 min walk test compared with placebo (20.5% versus 12.6%; P = 0.003) 53 . Elsewhere, testosterone-associated
Skeletal muscle index
Absolute muscle mass (in kg) normalized for height (muscle mass in kg divided by height (in m)).
Absolute muscle mass
Muscle mass consisting of all limbs and muscle from visceral organs.
increases in lean mass were accompanied by improvements in handgrip strength, knee extension and leg press and chest press exercises 415, 416 . A meta-analysis of testosterone supplementation found effect sizes of 0.47 (95% CI 0.12-0.84) for upper and 0.63 (95% CI 0.03-1.28) for lower extremity strength 417 , without sustained improvements in body composition 418 . Healthy men with reduced levels of testosterone had no improvements in muscle strength or mobility after 6 months of supplementation 350 . Another trial of testosterone treatment found improved stair-climbing power and strength 351 . Improvements in lean mass do not directly result in improved function after testosterone therapy 409 . With ageing, muscle strength often drops before muscle mass 73 . The nonlinear relationship between mass and function suggests that hypertrophy rather than muscle fibre hyperplasia materializes without neuronal plasticity. A reason for the observed significance in some studies might be a patient's intrinsic threshold for functional impairment. Frail older adults with testosterone deficiency could require minimal incremental gains in mass to realize benefit. Therefore, we suggest an individualized approach. Comorbidity and health status, small sample sizes, minimal changes in testosterone levels following treatment and the lack of practice sessions before initiating strength testing could have contributed to the negative findings. Areas of future research should identify responders to androgen supplementation in those with low lean mass or strength.
Testosterone potentially augments diet-induced loss of fat mass in individuals with BMI ≥30 kg/m 2 and low testosterone levels. Over 56 weeks, testosterone-treated participants (mean age 53 years) had greater reductions in fat mass (mean between-group difference 2.9 kg; P = 0.04) and visceral fat (−2,678 mm 2 ; P = 0.04) than controls. Testosterone-treated participants also had greater lean mass regain during weight maintenance (mean between-group difference 3.4 kg; P = 0.002) following the very-low-energy diet, suggesting that weight loss was exclusively fat mass 419 . As multicomponent interventions can attenuate lean mass losses, studies should evaluate whether testosterone replacement helps preserve muscle and bone mass during weight loss in patients with sarcopenic obesity.
Adverse events associated with testosterone supplementation include polycythemia 420 , possible cardiovascular events 421 , venous thromboembolism 422 and prostatism 423 . Those who favour supplementation cite a lack of credible evidence related to cardiovascular risk 424 . Future cost-benefit analyses should compare the relative benefits regarding body and bone composition with disability risk. 426 . Enobosarm, a non-steroidal SARM, successfully increased muscle mass and physical function in patients without cancer and in those with advanced lung, colorectal or breast cancer or lymphoma [427] [428] [429] . Other studies showed increases in lean mass without improvements in strength or physical performance in patients with sarcopenia 428, 430 . Early trials demonstrated a greater total lean mass of 1.3 kg (P < 0.001), better physical function as measured by reduced stair climb time (P = 0.013), a trend towards lower blood levels of glucose of 6.9 ± 2.5 mg/dl (P = 0.052) and lower insulin sensitivity (−27.5% versus 2.6%; P = 0.013) with 3 mg per day of GTx-024 (an orally bioavailable nonsteroidal SARM) than with placebo 429 . Enobosarm significantly increased lean mass compared with baseline (1.0 kg, 95% CI −4.8 to 11.5; P = 0.046) versus controls (0.02 kg, 95% CI −5.8 to 6.7; P = 0.88). SARM treatment in older women with low lean mass, a self-reported mobility disability and a short physical performance battery score between 4 and 9 provided improvements in muscle mass without benefits of improved strength 430 . SARMs that have been developed in the past 5 years have not demonstrated adverse effects 431 and have restored cortical and trabecular bone in orchidectomized mice 432 . Transdermal SARMs could emerge in the future 433 . A review of SARMs has been conducted elsewhere 434 , but they could be of benefit to patients with sarcopenic obesity who require muscle mass improvements rather than strength. However, conclusive evidence is still needed.
Anamorelin. Anamorelin, an oral ghrelin analogue, is effective for improving appetite in patients with cancer cachexia and might hold promise in patients with sarcopenic obesity. Its anti-inflammatory and anabolic properties might counter the negative nitrogen balance observed in sarcopenia. Anamorelin is safe, well tolerated and stimulates appetite by promoting expression of GH, IGF1 and IGF-binding protein 3 (refs 435,436 ), which reverses muscle atrophy in mice 437 . A meta-analysis of 1,641 patients with cancer demonstrated improved total body weight, lean mass and quality of life (1.78, 95% CI 1.28-2.28, P < 0.001; 1.10, 95% CI 0.35-1.85, P = 0.004; 0.19, 95% CI 0.08-0.30, P = 0.0006, respectively) 438 . A review of four studies demonstrated high heterogeneity with improved symptom scores, and in three studies, improved lean mass was shown 439 . Anamorelin improved lean mass in patients with cancer cachexia compared with placebo (2.09 kg, 95% CI 0.94-3.25; P = 0.0006) 440 but failed to improve muscle power or handgrip strength in patients with inoperable nonsmall-cell lung cancer 441 . Lack of functional improvements were also observed in patients with unresectable non-small-cell lung cancer 442 . Adverse effects are no different than with placebo. It is unclear whether the improved lean mass observed in patients treated with anamorelin has differential effects on intramuscular fat in patients with sarcopenic obesity. As no studies have established improved function or strength, further evaluation is needed, particularly in the subset of patients with sarcopenic obesity who have low lean mass with intact muscle strength.
Myostatin inhibitors. Individuals with sarcopenia have elevated levels of myostatin 443 , a negative regulator of skeletal muscle growth development 444 . Myostatin is also expressed in adipose tissue and is inversely related to insulin resistance 445 . In vitro trials demonstrate that myostatin inhibitors increase muscle mass and strength 446 , suppress irisin, downregulate inflammatory cytokines and improve insulin resistance 447 . Its expression drops following weight loss because it directly influences adipocyte metabolism 448 , and myostatin inhibitors can directly inhibit muscle loss. Myostatin inhibitors reduce expression of myostatin in both aerobic and resistance exercise 449 and might be beneficial in treating sarcopenic obesity. Early data suggest improved physical function in patients with non-small-cell lung cancer 427 .
Interventions should directly measure changes in levels of myostatin and corresponding changes in muscle mass, strength, function and insulin sensitivity.
Vitamin K. Vitamin K might have a role in mitigating bone loss following intentional weight loss by inhibiting bone resorption 450 and osteoclast formation 451 . Its deficiency has been associated with increased risk of fragility fractures [452] [453] [454] [455] , particularly in patients who are malnourished 456, 457 . Vitamin K supplementation can restore serum levels of the vitamin 458, 459 and might increase bone resorption markers 460 . Conflicting data exist; in some studies, vitamin K antagonists demonstrate no differences in BMD or fracture rates 461 , while other data suggest lessening of steroid-induced BMD 462 and sex-specific improvements in insulin sensitivity 463 . One study 464 reported that over 3 years vitamin K supplementation was not implicated in the age-related changes in skeletal muscle or adipose tissue mass in older community-dwelling adults. Our understanding of the complex relationship between vitamin K and weight loss-induced effects on bone, muscle and fat in sarcopenic obesity is currently in its infancy 465 .
Mesenchymal stem cells. Muscle, bone and cartilage derived from mesenchymal cells share common precursor mesenchymal stem cells. In mice, transplantation of satellite cells into damaged muscle leads to self-renewal and muscle regeneration 466, 467 . An early human study suggests a role for mesenchymal stem cells in managing frailty 468 . The cost, regulatory constraints and potential ethical barriers of applying such technology into clinical settings need to be addressed further.
Conclusions
The growing challenges associated with sarcopenic obesity will probably worsen with the changing demographic distribution of our ageing population. Effective evidencebased therapies can be helpful for improving physical function in older adults. We encourage further agreement on defining sarcopenic obesity within both research and clinical settings. In our opinion, a lack of a consensus definition is one of the greatest limitations to advancing the science. Without being able to accurately identify populations of patients, there will be continued difficulties in targeting further obesity subtypes. Clarifying the mechanisms that contribute to sarcopenic obesity might elucidate novel therapies to improve function, quality of life and prevent institutionalization. A number of novel therapies independently hold promise or could be considered adjunctively for those who have struggled with a lifetime of reduced motivation. These potential strategies should be key research questions in future work.
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This is a randomized trial of testosterone therapy in symptomatic older men that demonstrates no benefit in vitality or walking distance following supplementation. 54 
